Nothing said here yet.
to join the conversation.
| Faddis JonathanSVP, Gen. Counsel, Secretary | Sell | 3,515 | $1.1M | Wed, Oct 14 |
| Faddis JonathanSVP, Gen. Counsel, Secretary | Sell | 975 | $291.8K | Wed, Oct 14 |
| Faddis JonathanSVP, Gen. Counsel, Secretary | Sell | 708 | $211.1K | Wed, Oct 14 |
| Rizzo Daniel JEVP, Sales, Consulting, & Svcs | Sell | 4,520 | $1.2M | Fri, Oct 2 |
| Rizzo Daniel JEVP, Sales, Consulting, & Svcs | Sell | 321 | $88.7K | Fri, Oct 2 |
| Schwenger Thomas D.Pres. & Chief Customer Officer | Sell | 1,000 | $265.2K | Mon, Sep 14 |
| Hung PriscillaDirector | Sell | 750 | $195.8K | Wed, Sep 9 |
| Schwenger Thomas D.Pres. & Chief Customer Officer | Sell | 10,000 | $2.8M | Thu, Aug 27 |
| Schwenger Thomas D.Pres. & Chief Customer Officer | Sell | 33,181 | $8.3M | Thu, Aug 13 |
| Schwenger Thomas D.Pres. & Chief Customer Officer | Sell | 1,819 | $456.6K | Thu, Aug 13 |
| Schwenger Thomas D.Pres. & Chief Customer Officer | Sell | 1,000 | $241.9K | Thu, Aug 13 |
Veeva Systems has delivered a 63.4% gain over the past three years, and after a strong run into 2026 the obvious question is whether that kind of share price performance is still grounded in the cash the business can generate.
Veeva Systems recently hosted its Commercial Summit Europe in Copenhagen, where leaders from AstraZeneca, Bristol Myers Squibb, Roche and others shared how industry specific AI and Veeva’s Commercial Cloud and Data Cloud tools support customer engagement,…
AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB et d'autres entreprises présenteront de nouvelles approches en matière d'engagement client connecté, de MLR automatisé et d'impact médical BARCELONE, Espagne, 29 octobre 2026 /PRNewswire/ --…
AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB und weitere Unternehmen stellen neue Ansätze für vernetzte Kundenbindung, agentenbasiertes MLR und medizinische Wirkung vor BARCELONA, Spanien, 29.
AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB y otras compañías mostrarán nuevos enfoques para la interacción conectada con el cliente, procesos MLR basados en agentes e impacto médico BARCELONA, España, 29 de octubre de 2026 /PRNewswire/ --…
AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB and more to showcase new approaches for connected customer engagement, agentic MLR, and medical impact BARCELONA, Spain, Oct.
Veeva Systems (VEEV) moves back into focus as investors look ahead to fiscal Q3 2027 results, with analysts projecting EPS of $1.68 and highlighting momentum in AI driven CRM adoption. Recent trading tells a story of rebuilding confidence in Veeva Systems.
Veeva Systems is scheduled to post its third-quarter results soon, and analysts project a double-digit earnings growth.
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $318.18, denoting a -1.5% move from the preceding trading day.
Investment management company Vulcan Value Partners recently released its third-quarter 2026 investor letter. The letter can be downloaded here.
For questions about this article or underlying research, email [email protected].
For questions about this article or underlying research, email [email protected].